Elutia (ELUT) FCF Margin (2019 - 2026)

Elutia (ELUT) posted FCF Margin of 265.22% for Q1 2026, up 66.2% sequentially from 784.59% in Q4 2025, and up 4515.0% YoY from 5.75% in Q1 2025.

Elutia (ELUT) FCF Margin (2019 - 2026) Analysis & Trends

Elutia has reported FCF Margin for 8 years, with the latest figure at 265.22% in Q1 2026.

Quarterly FCF Margin rose 4515.0% year-over-year to 265.22% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 286.68% (down 9703.0% YoY) and the FY2025 annual result came in at 379.78%, down 21864.0% from the prior year.
FCF Margin climbed to 265.22% in Q1 2026 per ELUT's latest filing, from 784.59% in the prior quarter.
Over five years, FCF Margin peaked at 38.95% in Q2 2023 and troughed at 784.59% in Q4 2025.
A 5-year average of 173.3% and a median of 96.29% in 2022 frame the typical range for FCF Margin.
The sharpest annual moves came in 2023 and 2025: FCF Margin surged 4773 bps in 2023, then sank 34599 bps in 2025.
Over 5 years, FCF Margin stood at 81.66% in 2022, then tumbled by 90 bps to 154.89% in 2023, then plunged by 183 bps to 438.6% in 2024, then sank by 79 bps to 784.59% in 2025, then jumped by 66 bps to 265.22% in 2026.
According to Business Quant data, FCF Margin over the past three periods registered 265.22%, 784.59%, and 106.23% for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	FCF Margin (Qtr)
1	Abbott Laboratories	198.70 Bn	193.10 Bn	7.27 Bn	15.81%
2	Stryker	125.85 Bn	122.37 Bn	4.50 Bn	16.07%
3	Medtronic	118.44 Bn	109.22 Bn	6.41 Bn	21.26%
4	Boston Scientific	72.64 Bn	72.10 Bn	3.85 Bn	23.50%
5	Edwards Lifesciences	51.94 Bn	47.69 Bn	1.35 Bn	33.60%
6	Dexcom	34.48 Bn	32.53 Bn	830.00 Mn	14.10%
7	GE HealthCare Technologies	33.60 Bn	31.49 Bn	2.18 Bn	1.28%
8	Koninklijke Philips	26.30 Bn	22.98 Bn	4.55 Bn	5.32%
9	Steris	23.00 Bn	22.52 Bn	684.20 Mn	18.73%
10	Elutia	39.87 Mn	19.98 Mn	1.45 Mn	-352.70%

Download Data